Wonder Sir Founder Chen Yiwei on China’s Rare Disease Definition and Recent Policy Boost for Foreign CGT Investment
Motivated by a profound sense of purpose and deeply moved by the suffering of Chinese rare disease patients, Chen Yiwei,
Shanghai Enhances Payment Mechanisms to Drive Pharma and Medical Innovation
Shortly after the National Healthcare Security Administration (NHSA) introduced its more industry-friendly renewal rules for older NRDL-negotiated drugs, the Shanghai
China Implements More Moderate and Predictable Price Reduction for Older NRDL-Negotiated Drugs
In late June, the National Healthcare Security Administration (NHSA) commenced the 2023 National Reimbursement Drug List (NRDL) Dynamic Update, aiming
Chinese Organization for Rare Disorders Founder Kevin Huang: China is Focusing on Solving Orphan Drug Access Issues
On a beautiful Wednesday morning, just after celebrating July 4th, I sat down with Kevin Huang, the visionary founder of
Navigating China's Access Landscape for Orphan Therapies: Insights into Funding Pathways
Welcome back to the final installment of our three-part series exploring China's access landscape of rare disease therapies.
Understanding China’s Access Environment for Orphan Therapies: Advancing Policies and Diagnosis & Treatment Capacities
In our previous installment, we delved into the distinctive characteristics and commercial challenges surrounding rare diseases, highlighting a comprehensive solution
Understanding China’s Access Environment for Orphan Therapies: 3 Key Considerations
Biopharmaceutical companies face distinctive challenges when it comes to developing and commercializing treatments for rare diseases, as these conditions affect
